Lenvatinib and Cabozantinib were also able to reduce cell proliferation (Fig. 3a), and at low extend increased caspase-3 activity in HepG2 cells (Fig. 3b), in HCC cells cultured in monolayer. The gene discussed is CASP3; the disease is hepatocellular carcinoma.